Dual antiplatelet therapy after coronary stenting

Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice

(2016) Weihong Fan et al.   AMERICAN JOURNAL OF CARDIOLOGY

Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents

(2016) Xin-Lin Zhang et al.   ANNALS OF INTERNAL MEDICINE

Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents

(2016) James B. Hermiller et al.   JACC-Cardiovascular Interventions

Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?

(2016) Sara Ariotti et al.   JACC-Cardiovascular Interventions

Scaffold Thrombosis After Percutaneous Coronary Intervention With ABSORB Bioresorbable Vascular Scaffold

(2016) Michael J. Lipinski et al.   JACC-Cardiovascular Interventions

Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention

(2016) Robert W. Yeh et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

(2016) John A. Bittl et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

(2016) Usman Baber et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

(2016) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials

(2016) Salvatore Cassese et al.   LANCET

1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis

(2016) Gregg W Stone et al.   LANCET

Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54

(2015) Marc P. Bonaca et al.   EUROPEAN HEART JOURNAL

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

(2015) S. Schulz-Schupke et al.   EUROPEAN HEART JOURNAL

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

(2015) Marco Roffi et al.   EUROPEAN HEART JOURNAL

Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective

(2015) Tomas Jernberg et al.   EUROPEAN HEART JOURNAL

Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents

(2015) Dean J. Kereiakes et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2015) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

(2015) Robert W. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin

(2015) Martine Gilard et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Very Late Scaffold Thrombosis

(2015) Lorenz Räber et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates

(2015) Marco Valgimigli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2015) Gennaro Giustino et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

(2015) Sammy Elmariah et al.   LANCET

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

(2015) Marc P. Bonaca et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike

(2015) Francesco Franchi et al.   PROGRESS IN CARDIOVASCULAR DISEASES

What about the risk of thrombosis with bioresorbable scaffolds?

(2015) Davide Capodanno et al.   EuroIntervention

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

(2015) Davide Capodanno et al.   EuroIntervention

Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions

(2014) Davide Capodanno et al.   Circulation-Cardiovascular Interventions

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)

(2014) et al.   EUROPEAN HEART JOURNAL

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

Current Status of Bioresorbable Scaffolds in the Treatment of Coronary Artery Disease

(2014) Jens Wiebe et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy

(2014) Antonio Colombo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

(2014) Ezra A. Amsterdam et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

(2014) Jean-Philippe Collet et al.   LANCET

Novel antiplatelet agents in acute coronary syndrome

(2014) Francesco Franchi et al.   Nature Reviews Cardiology

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents

(2013) Dominick J. Angiolillo et al.   American Journal of Cardiovascular Drugs

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2013) Cheol Whan Lee et al.   CIRCULATION

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)

(2013) M. Valgimigli et al.   EUROPEAN HEART JOURNAL

Risk of Stent Thrombosis Among Bare-Metal Stents, First-Generation Drug-Eluting Stents, and Second-Generation Drug-Eluting Stents

(2013) Tomohisa Tada et al.   JACC-Cardiovascular Interventions

Stent Thrombosis With Drug-Eluting Stents

(2013) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis

(2013) Gianluca Campo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2012) Marco Valgimigli et al.   CIRCULATION

Antithrombotic Therapy in Patients With Chronic Kidney Disease

(2012) Davide Capodanno et al.   CIRCULATION

The Evolution of Antiplatelet Therapy in the Treatment of Acute Coronary Syndromes

(2012) Dominick J. Angiolillo   DRUGS

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization

(2012) Matthew T. Roe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

(2011) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting

(2011) John Eikelboom et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic Therapy in the Elderly

(2010) Davide Capodanno et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes

(2010) Roxana Mehran et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Stent Thrombosis

(2010) David R. Holmes et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction

(2009) Sumeet Subherwal et al.   CIRCULATION

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of “Nuisance” Bleeding on Clopidogrel Compliance in Patients Undergoing Intracoronary Drug-Eluting Stent Implantation

(2008) Probal Roy et al.   AMERICAN JOURNAL OF CARDIOLOGY